LSD (acetate)
LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics[1].
Product Specifications
UNSPSC
12352209
Target
Biochemical Assay Reagents
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.02
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
Molecular Formula
C39H72N14O13S2.xC2H4O2
Molecular Weight
1009.20 (free base)
References & Citations
[1]Zhang L, et al. Lymphatic zip codes in premalignant lesions and tumors. Cancer Res. 2006 Jun 1;66 (11) :5696-706.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MTOR (Serine/threonine-Protein Kinase mTOR, FK506-Binding Protein 12-rapamycin Complex-Associated Protein 1, FKBP12-rapamycin Complex-Associated Protein, Mammalian target of rapamycin, mTOR, Mechanistic target of rapamycin, Rapamycin and FKBP12 target 1, Rapamycin target Protein 1, MTOR, FRAP, FRAP1, FRAP2, RAFT1, RAPT1) discontinued
MTOR (Serine/threonine-Protein Kinase mTOR, FK506-Binding Protein 12-rapamycin Complex-Associated Protein 1, FKBP12-rapamycin Complex-Associated Protein, Mammalian target of rapamycin, mTOR, Mechanistic target of rapamycin, Rapamycin and FKBP12 target 1, Rapamycin target Protein 1, MTOR, FRAP, FRAP1, FRAP2, RAFT1, RAPT1) discontinued
Lentiviral mouse Lrrc10 shRNA (UAS) - Lentiviral mouse Lrrc10 shRNA (UAS, iRFP) (25)